Chester County News and Community Website
RADNOR, PA — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) disclosed encouraging preliminary outcomes from a study on NRX-101, an investigational drug designated as a breakthrough therapy. The drug demonstrated a promising, …
NRx Pharmaceuticals Breakthrough Drug Shows Potential to Reduce Suicide Risk in Bipolar Depression Patients Read More
PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) has received approval from the U.S. Food and Drug Administration (FDA) to commence a Phase 1 clinical trial for CTIM-76, a pioneering …
FDA Clears Context Therapeutics to Begin Trial for Novel Cancer Therapy Read More
MALVERN, PA — YPrime, a leading figure in clinical trial technology, has released a new report titled “Insights into CNS Clinical Trials.” This comprehensive study sheds light on the pivotal …
New Report Highlights eCOA’s Role in Streamlining CNS Clinical Trials Read More MALVERN, PA — YPrime has unveiled its latest innovation, the Tender Swollen Joint Count (TSJC) assessment. This tool is designed to revolutionize the way disease activity affecting joints is measured …
YPrime Introduces Innovative Assessment Tool to Enhance Clinical Trials for Autoimmune Diseases Read More
MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) has made a breakthrough in an ongoing study of Alzheimer’s disease. Their novel Alzheimer’s drug, buntanetap, which specifically targets neurotoxic proteins, has …
Groundbreaking Alzheimer’s Study Reveals Potential for Progression-Slowing Therapy Read More
RADNOR, PA — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) recently announced its decision to proceed with the Phase 3 RAISE trial of intravenous (IV) ganaxolone for treating refractory status epilepticus (RSE), …
Marinus Pharmaceuticals Continues Phase 3 Trial for Epilepticus Treatment Despite Setback Read More RADNOR, PA — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) recently announced the completion of data collection in its pivotal Phase 2b/3 study of NRX-101. This milestone, known as data-lock, signifies the …
NRx Pharmaceuticals Advances in Breakthrough Bipolar Depression Treatment Read More
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company at the forefront of gene therapy innovation, has recently announced a groundbreaking development in the fight against retinitis pigmentosa (RP), …
Ocugen’s Leap into Phase 3 Trials: A Beacon of Hope for Retinitis Pigmentosa Patients Read More
PLYMOUTH MEETING, PA — In a significant development for patients with Prader-Willi syndrome (PWS), Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) recently announced the initiation of a global Phase 3 registrational …
Harmony Biosciences Launches Phase 3 Trial for Potential Prader-Willi Syndrome Treatment Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focusing on discovering, developing, and commercializing transformative therapies to cure blindness diseases, announced a significant milestone in its Phase 1/2 …
Ocugen Advances in Pioneering Gene Therapy for Geographic Atrophy with DSMB Approval to Proceed to Medium Dose in Clinical Trial Read More